The biotech has stopped a weight loss maintenance trial of its weekly GLP-1 pill. FirstWord Pharma has the details on the decision.
Recap by typeshit. Full story at FirstWord Pharma.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
The post points out that drugs like Ozempic, Wegovy and Mounjaro slow how fast the stomach empties, which it says creates a serious risk for patients going into surgery.
A shared excerpt points to TRIUMPH-2 results on how well retatrutide works and how safe it is. The snippet gives no numbers, so the full piece has the data.
Loading…